P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL

• M. Amatangelo,
• Y. Cheng,
• W. Pierceall,
• N. W. van de Donk,
• S. Lonial,
• M. Wang,
• J. Emerson,
• K. Hong,
• P. Maciag,
• T. Peluso,
• A. Gandhi,
• A. Thakurta

Affiliations

M. Amatangelo

1 Bristol Myers Squibb, Princeton, NJ, United States of America

Y. Cheng

1 Bristol Myers Squibb, Princeton, NJ, United States of America

W. Pierceall

1 Bristol Myers Squibb, Princeton, NJ, United States of America

N. W. van de Donk

2 Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands

S. Lonial

3 Winship Cancer Institute, Emory University, Atlanta, GA, United States of America

M. Wang

1 Bristol Myers Squibb, Princeton, NJ, United States of America

J. Emerson

1 Bristol Myers Squibb, Princeton, NJ, United States of America

K. Hong

1 Bristol Myers Squibb, Princeton, NJ, United States of America

P. Maciag

1 Bristol Myers Squibb, Princeton, NJ, United States of America

T. Peluso

4 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

A. Gandhi

1 Bristol Myers Squibb, Princeton, NJ, United States of America

A. Thakurta

1 Bristol Myers Squibb, Princeton, NJ, United States of America